Recently, the results of the secondary analysis of VITAL research data were published in JAMA Network Open, a subsidiary of the Journal of the American Medical Association. Data shows that taking vitamin D is associated with a lower overall risk of developing advanced (metastatic or fatal) cancer, and weight can affect the association between them.
In December 2005, it was approved by the FDA as a first-line drug for the treatment of advanced kidney cancer. This is the only targeted drug approved by the FDA for the treatment of kidney cancer in the past 10 years, and it is a major progress in the treatment of kidney cancer. Sorafenib is the world's first approved multi-target anti-cancer drug.
Researchers discovered a new immune defense mechanism that is unknown so far. It is a mechanism orchestrated by lipid droplets (LDs), the cellular organelles can attract and eliminate invading pathogens.
Recently, the team of Professor Jin Hongjun from the Molecular Imaging Center of Sun Yat-sen University No.5 Hospital and the Tumor Center of Sun Yat-sen University No.5 Hospital explored a novel method to improve hypoxia in photodynamic therapy, and preliminarily found that oxyphotodynamic therapy combined with metformin has the potential to treat triple-negative breast cancer.